Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) shares hit a new 52-week high on Thursday . The stock traded as high as $36.58 and last traded at $36.56, with a volume of 1664742 shares. The stock had previously closed at $35.74.
A number of brokerages have commented on RHHBY. ValuEngine downgraded shares of Roche Holdings AG Basel from a “hold” rating to a “sell” rating in a research report on Tuesday, September 10th. Deutsche Bank raised shares of Roche Holdings AG Basel from a “hold” rating to a “buy” rating in a research report on Thursday, June 20th. UBS Group raised shares of Roche Holdings AG Basel from a “neutral” rating to a “buy” rating in a research report on Friday, July 26th. Liberum Capital downgraded shares of Roche Holdings AG Basel from a “buy” rating to a “hold” rating in a research report on Thursday, June 20th. Finally, Zacks Investment Research raised shares of Roche Holdings AG Basel from a “hold” rating to a “buy” rating and set a $37.00 price objective on the stock in a research report on Tuesday, July 9th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company’s stock. Roche Holdings AG Basel presently has a consensus rating of “Hold” and a consensus price target of $37.00.
The firm’s fifty day moving average price is $35.37 and its 200-day moving average price is $34.27. The firm has a market cap of $249.90 billion, a price-to-earnings ratio of 15.76, a PEG ratio of 2.25 and a beta of 0.49.
About Roche Holdings AG Basel (OTCMKTS:RHHBY)
Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases.
Recommended Story: Calculate Your Return on Investment (ROI)
Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.